Saturday, September 09, 2023
Brainomix has announced a collaborative effort with the TIPAL trial group to conduct a sub-study aimed at assessing the effectiveness of its e-Lung platform. The TIPAL trial, sponsored by the Norfolk and Norwich University Hospitals (NNUH) NHS Foundation Trust and funded by the National Institute of Health Research (NIHR), is a comprehensive, 52-week, multi-center investigation designed to evaluate the impact of lansoprazole, a commonly prescribed medication for indigestion and acid reflux, on patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF). IPF is characterized by a progressive decline in lung function, with individual disease trajectories varying.
The sub-study's objective is to enroll 298 patients who will undergo home spirometry tests to measure their forced vital capacity (FVC). Daily assessments at both baseline and 12 months post-randomization will be compared to evaluate the effect of lansoprazole on the absolute change in percent predicted FVC. Additionally, during the follow-up period, participants will be required to perform weekly spirometry assessments at home.
Concurrently, Brainomix will conduct its sub-study, utilizing its cutting-edge e-Lung platform, based in Oxford and powered by artificial intelligence (AI) image processing. This platform plays a pivotal role in standardizing the quantification of lung fibrosis on High-Resolution (HR) CT scans, offering a more precise identification of patients with progressive fibrosis. Central to this platform is the innovative imaging biomarker known as the weighted reticulovascular (WRV) score, which quantifies the extent of lung affected by reticulovascular abnormalities. Notably, this biomarker has demonstrated superior prognostic capabilities compared to traditional metrics. The primary objective of the sub-study is to ascertain the difference in WRV score change between lansoprazole and placebo treatments, specifically between baseline and 12 months post-randomization.
Dr. Peter George, Senior Medical Director at Brainomix and Clinical Lead for Interstitial Lung Disease (ILD) at Royal Brompton Hospital in London, expressed his enthusiasm for the collaboration with the TIPAL study group. He emphasized the significant potential of their AI technology to expedite clinical trials, identify more effective therapeutic options, and ultimately enhance the quality of life for individuals afflicted by IPF.
Professor Andrew Wilson, TIPAL Chief Investigator, underscored the value of incorporating Brainomix's advanced CT scanning technology into the TIPAL study. This partnership will not only ascertain whether lansoprazole improves CT scan abnormalities but also facilitate a comprehensive comparison of CT scan findings with home-based lung function assessments.
For additional information about the TIPAL study, which stands as the UK's largest government-funded pulmonary fibrosis trial, please visit https://www.uea.ac.uk/web/groups-and-centres/projects/tipal.
It's important to note that this study receives funding from the NIHR Health Technology Assessment program (NIHR127479).